Hypoalphalipoproteinemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hypoalphalipoproteinemia. 11 active patents protecting 2 drugs from 2+ originators. First major cliff: 2026. Daily refresh.

2
Approved drugs
11
Active US patents
66/100
Avg vulnerability
—
Annual revenue covered

Originators in Hypoalphalipoproteinemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Merck & Co. 10 patents Salix 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hypoalphalipoproteinemia. Each bar = one year. Y-axis scaled to peak year (6 patents).

6
26
2
27
2
30
1
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zocor
simvastatin
 Merck & Co. 10 70 — 2026-10-11
Tricor (Micronized)
FENOFIBRATE
 Salix 1 62 — 2033-05-31

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
9314447 Tricor (Micronized) method of use 62 2033-05-31
10300041 Zocor formulation 60 2027-04-26
10300041 Zocor formulation 60 2027-04-26
9597289 Zocor formulation 48 2030-02-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9597289 Zocor formulation 48 2030-02-23
9597289 Zocor formulation 48 2030-02-23
10300041 Zocor formulation 60 2027-04-26
10300041 Zocor formulation 60 2027-04-26
9314447 Tricor (Micronized) method of use 62 2033-05-31
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11

Related